口服氯化钾联用抗胆碱能药物与上消化道出血风险的相关性:一项队列研究
分析显示,联用抗胆碱能药物者上消化道出血发生率显著高于未暴露者(0.3% vs 0.1%,P=0.018),多因素分析中联用抗胆碱能药物与上消化道出血显著相关(OR 2.48,95%CI 1.11-6.51,P=0.022)。
要点
- 住院患者口服氯化钾联用抗胆碱能药物时上消化道出血风险显著增加(OR 2.48)。
- 血液肿瘤疾病患者接受抗凝治疗时上消化道出血风险亦显著增加(OR 6.61)。
- 联用抗胆碱能药物者出血事件中位时间为首次氯化钾剂量后7天。
核心结论
- 住院患者同时接受口服氯化钾和抗胆碱能药物治疗时,上消化道出血风险显著增加。
研究设计与样本
- 按是否联用抗胆碱能药物分为两组,比较上消化道出血发生率。
主要发现
- 联用抗胆碱能药物组上消化道出血发生率为0.3%,未暴露组为0.1%(P=0.018)。
- 从首次氯化钾剂量至出血事件的中位时间为7天(IQR 3-16.8)。
- 多因素分析显示联用抗胆碱能药物与上消化道出血显著相关(OR 2.48,95%CI 1.11-6.51,P=0.022)。
- 血液肿瘤疾病患者接受抗凝治疗与上消化道出血显著相关(OR 6.61,95%CI 1.96-22.25,P=0.002)。
临床怎么用
- 临床对住院患者口服氯化钾时应评估抗胆碱能药物联用情况,警惕上消化道出血风险。
- 对血液肿瘤疾病接受抗凝治疗的患者,联用口服氯化钾时需加强上消化道出血监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To determine whether oral potassium chloride (KCI) therapy with concomitant anticholinergic exposure among hospitalized patients is associated with an excess risk for upper gastrointestinal bleeding (UGIB). METHODS: A retrospective controlled study among hospitalized patients between January 2007 and April 2019 who were treated with oral KCI. Patients were divided into two groups: with or without concomitant exposure to agents with anticholinergic activity. Outcome was defined as any UGIB. RESULTS: The final sample included 13 728 subjects who received oral KCI treatment, of them 3542 (25.8%) had at least one documented overlap with an anticholinergic agent. Mean age was 67.6 (±17.2) and 6893 (50.2%) were females. Median KCI dose was 2.4 g (interquartile range [IQR] 1.2-5.4, n = 9416) with the majority (90.4%) being treated with the wax-matrix form (Slow-K). Twenty-six (0.2%) patients experienced an UGIB event. Univariate analysis demonstrated a significantly higher rate of UGIB among patients concomitantly treated with oral KCI and anticholinergics (0.3%) compared to those without anticholinergic exposure (0.1%, P = 0.018), with median 7 days (IQR 3-16.8) from first KCI dose to bleeding event. Multivariate analysis demonstrated that concomitant anticholinergic exposure (Odds Ratio 2.48, 95% Confidence Interval 1.11-6.51, P = 0.022) and anticoagulation treatment among patients with hemato-oncologic disease (OR 6.61, 95% CI 1.96-22.25, P = 0.002) were significantly associated with UGIB. CONCLUSION: Hospitalized patients treated concomitantly with oral KCI and anticholinergic agents have significantly increased risk for UGIB.
引用
- Gueta I, Markovits N, Halkin H, et al. Concomitant oral potassium chloride and anticholinergic therapy is associated with upper gastrointestinal bleeding: A cohort study. Br J Clin Pharmacol. 2020. PMID: 33068044. doi:10.1111/bcp.14616
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。